Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Implementing ALCOA+ for Gene Editing Analytical Data

EXECUTIVE SUMMARY

Implementing ALCOA+ for Gene Editing Analytics in a UK Regulatory Environment

CELL & GENE | RNA | BIOLOGICS

A stylized, 3D rendering of a DNA double helix in light blue and white, set against a soft-focus, light gray background.

For gene editing programs targeting UK and EU regulatory submissions, implementing the ALCOA+ framework for analytical data is a foundational requirement for a successful Investigational Medicinal Product Dossier (IMPD). This framework ensures that all characterization, potency, and safety data is Attributable, Legible, Contemporaneous, Original, and Accurate, plus Complete, Consistent, Enduring, and Available. Adherence to these principles provides regulators, including the MHRA, with verifiable evidence of product quality and control, directly impacting the timeline and success of clinical trial applications. This approach is modality-agnostic, applying to both viral vector systems and non-viral lipid nanoparticle (LNP) delivery platforms.

Frequently Asked Questions

What is the role of ALCOA+ in analytical development for gene editing therapies?

ALCOA+ is a data integrity framework that governs how analytical data is recorded and managed in GxP environments. For gene editing analytics, it ensures every data point related to vector characterization, potency assays, and off-target analysis is traceable, reliable, and accurate, which is fundamental for MHRA submissions and other global regulatory bodies.

How does Franklin Biolabs ensure data integrity for novel LNP-based RNA therapeutics?

We apply ALCOA+ principles to the entire analytical lifecycle. For lipid nanoparticle (LNP) therapy programs, this includes rigorous documentation for particle characterization, RNA payload integrity, and encapsulation efficiency. Our processes are designed to produce verifiable data packages that support the unique CMC requirements of non-viral delivery systems.

Can a robust data package accelerate IND or IMPD submissions for CRISPR/Gene Editing programs?

Yes. A data package built on ALCOA+ principles minimizes regulatory questions and delays. By ensuring all analytical results are complete, consistent, and accurate from the outset, we help sponsors build a stronger submission file, supporting an 18-24 month timeline to get candidates to IND.

Data Integrity for Gene Editing Analytics: An MHRA & ICH Perspective

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Proven Intelligence in Regulatory-Compliant Analytics.

The analytical data package for a gene editing therapeutic forms the bedrock of any successful IMPD submission. For UK and EU authorities, data integrity serves as a direct reflection of manufacturing process control and product understanding. Implementing the ALCOA+ framework provides a systematic approach to ensure data meets the highest standards of quality and traceability.

This framework is particularly relevant for the complex analytics required by nuclease platforms like CRISPR-Cas9. Quantifying the efficiency of on-target edits while simultaneously demonstrating control over potential off-target events requires an unimpeachable data trail.

Applying ALCOA+ to Advanced Modalities

The principles of data integrity extend across all delivery systems, from established viral vectors to emerging non-viral platforms.

  • AAV-Based Systems: For AAV-delivered gene editors, analytical data must rigorously document vector identity, purity, and potency. As research demonstrates, strategies to increase editing specificity are a key focus (PMID: 33359790). The analytical methods used to verify the reduction of off-target activity in nonhuman primate models must produce data that is contemporaneous, original, and accurate to be credible for regulatory review.

  • LNP & RNA Payloads: The development of novel biodegradable ionizable lipids for mRNA delivery introduces new analytical challenges (PMID: 40060499). An ALCOA+ compliant approach ensures that data from particle size analysis, encapsulation efficiency, and payload integrity assays are consistently and completely captured, providing a reliable basis for CMC decision-making.

Our analytical teams operate within a >100,000 sq ft facility designed for these exact challenges, ensuring that all GxP-compliant data is managed with the highest level of integrity. The facility’s infrastructure supports the complex workflows needed for next-generation therapies.

A Framework for Global Submissions

While this focus is on the UK’s MHRA requirements, the ALCOA+ framework aligns with harmonized international guidelines (ICH), including those of the FDA. By building a data package compliant with these principles from the start, therapeutic developers are better positioned for multi-jurisdictional submissions. This proactive approach to data governance minimizes the risk of costly delays during regulatory review cycles.

The core of our analytical services, which are part of the broader Vector | CMC | Analytics Services, is to generate data that is scientifically sound and regulatorily robust. This philosophy is a key contributor to the 100% successful IND rate achieved by our core scientific leadership since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities